ISA - Interdisciplinary Study Association GmbH

Running trials

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

  NCT06671496· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

  NCT06878404· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Source

• Recruiting

  A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  2023-505121-14-00· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Source

• Active, not recruiting

  A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas

  2023-505122-34-00· Phase 3· Source

• Active, not recruiting

  A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

  NCT06136741· Phase 2· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriasis2 recruiting
• Psoriatic arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis

  2024-517814-13-00· Phase 2· Source

• Completed

  Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.

  NCT06447506· Phase 2· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Source

• Completed

  A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

  NCT05999799· Phase 2· Source

• Completed

  Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

  NCT05916365· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

  NCT05896527· Phase 2· Source

• Completed

  An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)

  2022-501850-12-00· Phase 2· Source

• Completed

  Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

  NCT05469464· Phase 2· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Source

• Completed

  Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206· Phase 3· Source

• Completed

  A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

  NCT03818035· Phase 3· Source